The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive Behaviors in Childhood and Adolescent Autism
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712 · cited 2×
“The Obsessions and Compulsions Checklist (CY-BOCS O-C Checklist) (Goodman et al, 1989), which lists past and present occurrence of different OCD symptoms, was used at baseline to assess the range of obsessive-compulsive symptoms and to generate a list of symptoms that was then used as reference for…”
MethodThe Yale-Brown Obsessive-Compulsive Scale: Measures of internal consistency
Kim, S. W., Dysken, M. W., Pheley, A. M., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,359
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 3×
“The composite measure more closely parallels the way the CGI-AD measure has been used in other trials (Research Units on Pediatric Psychopharmacology (RUPP) Autism Network, 2002) where the focus was on global behavior, rather than core features of autism such as language and social reciprocity.”
BackgroundMethodInfluentialThe developmental role of serotonin: news from mouse molecular genetics
Gaspar, P., Cases, O., & Maroteaux, L. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1256 · Cited by 1,297
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle, C. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110037005 · Cited by 556
Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys
Chugani, D. C., Muzik, O., Rothermel, R., Behen, M., Chakraborty, P., Mangner, T., Da Silva, E. A., & Chugani, H. T. (1997) · Annals of Neurology · doi:10.1002/ana.410420420 · Cited by 399
The serotonin system in autism
Cook, E. H., & Leventhal, B. L. (1996) · Current Opinion in Pediatrics · doi:10.1097/00008480-199608000-00008 · Cited by 393
Gordon, C. T. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180039004 · Cited by 390
Clomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder
(1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320054008 · Cited by 388
Cited by
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Management of Children With Autism Spectrum Disorders
Myers, S. M., Johnson, C. P., & the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2362 · Cited by 1,125
Volkmar, F., Siegel, M., Woodbury-Smith, M., King, B., McCracken, J., & State, M. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.10.013 · Cited by 848
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
Leekam, S. R., Prior, M. R., & Uljarevic, M. (2011) · Psychological Bulletin · doi:10.1037/a0023341 · Cited by 612
Advances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
The serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531
“…studies suggested that serotonin reuptake inhibitors relieve symptoms of irritability and rigid-compulsive behavior in autism (Gordon et al., 1993, Hollander et al., 2005, Hollander et al., 2012); however studies in children have been less supportive, perhaps because of greater adverse events in…”
BackgroundPardo, C. A., & Eberhart, C. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00102.x · Cited by 514
King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Self-citationSilverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.201 · Cited by 438
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
Sutcliffe, J. S., Delahanty, R. J., Prasad, H. C., McCauley, J. L., Han, Q., Jiang, L., Li, C., Folstein, S. E., & Blakely, R. D. (2005) · The American Journal of Human Genetics · doi:10.1086/432648 · Cited by 392
“Repetitive behaviors and associated anxiety in autism and OCD are often effectively treated with SSRIs, targeting the SERT protein (Hollander et al. 2005).”
InfluentialA Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
“No significant differences between fluoxetine and placebo were reported for side effects (Hollander et al., 2005) (evidence Ib).”
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
Hollander, E., Soorya, L., Chaplin, W., Anagnostou, E., Taylor, B. P., Ferretti, C. J., Wasserman, S., Swanson, E., & Settipani, C. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10050764 · Cited by 224
Self-citationAn update on pharmacotherapy for autism spectrum disorder in children and adolescents
Ji, N. Y., & Findling, R. L. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000132 · Cited by 217
Serotonin and dopamine transporter binding in children with autism determined by SPECT
Makkonen, I., Riikonen, R., Kokki, H., Airaksinen, M. M., & Kuikka, J. T. (2008) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2008.03027.x · Cited by 169
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Wheeler, D. M., Silove, N., & Hazell, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub2 · Cited by 131
Posey, D. J., Aman, M. G., McCracken, J. T., Scahill, L., Tierney, E., Arnold, L. E., Vitiello, B., Chuang, S. Z., Davies, M., Ramadan, Y., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.028 · Cited by 131
Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“…trials have found beneficial effects of the SRIs clomipramine, fluvoxamine, and fluoxetine for OCD-like behavior in ASD (Gordon et al, 1993; Hollander et al, 2005; McDougle et al, Autism: from biomarkers to therapeutics J Veenstra-VanderWeele and RD Blakely…”
BackgroundNeurobiological correlates of social functioning in autism
Neuhaus, E., Beauchaine, T. P., & Bernier, R. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.05.007 · Cited by 122
Compulsivity, impulsivity, and the DSM-5 process
Berlin, G. S., & Hollander, E. (2014) · CNS Spectrums · doi:10.1017/s1092852913000722 · Cited by 120
Self-citationPosey, D. J., Wiegand, R. E., Wilkerson, J., Maynard, M., Stigler, K. A., & McDougle, C. J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.599 · Cited by 117
Reddihough, D. S., Marraffa, C., Mouti, A., O’Sullivan, M., Lee, K. J., Orsini, F., Hazell, P., Granich, J., Whitehouse, A. J. O., Wray, J., et al. (2019) · JAMA · doi:10.1001/jama.2019.14685 · Cited by 99
Matheson, B. E., & Douglas, J. M. (2017) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-017-0103-7 · Cited by 81
Psychopharmacology in autism: an update
Canitano, R., & Scandurra, V. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.015 · Cited by 79
Masi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Chantiluke, K., Barrett, N., Giampietro, V., Santosh, P., Brammer, M., Simmons, A., Murphy, D. G., & Rubia, K. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3837-2 · Cited by 63
“2007) and to improve communication, social interaction and stereotyped behaviours in children with ASD (DeLong et al. 2002; DeLong et al. 1998; Hollander et al. 2005), albeit citalopram was not effective (King et al.”
BackgroundHerscu, P., Handen, B. L., Arnold, L. E., Snape, M. F., Bregman, J. D., Ginsberg, L., Hendren, R., Kolevzon, A., Melmed, R., Mintz, M., et al. (2020) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-019-04120-y · Cited by 62
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial
DeVane, C. L., Charles, J. M., Abramson, R. K., Williams, J. E., Carpenter, L. A., Raven, S., Gwynette, F., Stuck, C. A., Geesey, M. E., Bradley, C., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2271 · Cited by 60
Chantiluke, K., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., Murphy, D. G., & Rubia, K. (2015) · Cerebral Cortex · doi:10.1093/cercor/bht365 · Cited by 59
“…be focused on in future research, particularly as protracted courses of Fluoxetine are used in the clinical trials that report an improvement in behavior in ADHD (Barrickman et al. 1991; Gammon and Brown 1993; Quintana et al. 2007) and ASD children (DeLong et al. 1998, 2002; Hollander et al. 2005).”
BackgroundInfluentialEmerging drugs for the treatment of symptoms associated with autism spectrum disorders
Wink, L. K., Plawecki, M. H., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.487860 · Cited by 36
Psychopharmacology of Autism Spectrum Disorder
Siegel, M. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.006 · Cited by 27
Martin, M. M., Liu, Y., & Wang, Z. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.09.015 · Cited by 26
Pharmacogenomic Medicine in Autism: Challenges and Opportunities
Bowers, K., Lin, P.-I., & Erickson, C. (2015) · Pediatric Drugs · doi:10.1007/s40272-014-0106-0 · Cited by 22
Deserno, M. K., Bathelt, J., Groenman, A. P., & Geurts, H. M. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-022-01986-9 · Cited by 22
Bremer, A., Giacobini, M., Nordenskjöld, M., Brøndum‐Nielsen, K., Mansouri, M., Dahl, N., Anderlid, B., & Schoumans, J. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30954 · Cited by 17
“…genomic regions associated with ASD [Ingram et al., 2000; Vincent et al., 2000, 2006; Wassink et al., 2001b; Shao et al., 2003; Ramoz et al., 2004; Hollander et al., 2005; Philippi et al., 2005; Bacchelli and Maestrini, 2006; Curran et al., 2006; Feuk et al., 2006; Vorstman et al., 2006a,b;…”
BackgroundMethodSinzig, J., & Lehmkuhl, G. (2007) · Psychopathology · doi:10.1159/000105531 · Cited by 14
Cardiac and hepatic side effects of fluoxetine in male and female adolescent rats
Babaaeyan, H., Sakhaie, N., Sadegzadeh, F., Saadati, H., & Niapour, A. (2024) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12963 · Cited by 4
Metadata
- Authors
- Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., & Iyengar, R.
- Venue
- Neuropsychopharmacology
- Published
- 2004-12-15
- Volume
- 30
- Issue
- 3
- Pages
- 582-589
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2007445647
- Cited by
- 408
- References
- 27
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.